STAT3: The "achilles" heel for AML?

Blood

Volumn 123, Issue 1, 2014, Pages 1-2

  Rezvani, Katayoun ^a   Barrett, John ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; SMALL INTERFERING RNA; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TH17 CELL; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84891820597     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-537092     Document Type: Review

References (9)

1. Hossain DMS, Dos Santos C, Zhang Q, et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood. 2014;123(1):15-25.
2. Rezvani K, Brody JD, Kohrt HE, et al. Cancer vaccines and T cell therapy. Biol Blood Marrow Transplant. 2013; 19(1 Suppl):S97-S101.
3. Rezvani K, Yong AS, Mielke S, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD81 T cells in myeloid malignancies. Haematologica. 2011; 96(3):432-440.
4. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
5. Rébé C, Végran F, Berger H, Ghiringhelli F. STAT3 activation: A key factor in tumor immunoescape. JAK-STAT. 2013;2(1):e23010.
6. Zhao M, Jiang B, Gao FH. Small molecule inhibitors of STAT3 for cancer therapy. Curr Med Chem. 2011;18(26): 4012-4018.
7. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005; 11(12):1314-1321. (Pubitemid 41752912)
8. Kortylewski M, Kujawski M, Herrmann A, et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy. Cancer Res. 2009;69(6):2497-2505.
9. Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002; 99(1):252-257.